Shopping Cart 0
Cart Subtotal
USD 0

Ependymoma - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Ependymoma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma-Pipeline Review, H2 2018, provides an overview of the Ependymoma (Oncology) pipeline landscape.

Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including general health, the size and position of the tumour, and whether it has spread to other parts of the brain or spinal cord.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ependymoma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ependymoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Ependymoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ependymoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ependymoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ependymoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ependymoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ependymoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 3

Ependymoma-Overview 4

Ependymoma-Therapeutics Development 5

Ependymoma-Therapeutics Assessment 11

Ependymoma-Companies Involved in Therapeutics Development 19

Ependymoma-Drug Profiles 25

Ependymoma-Dormant Projects 184

Appendix 185


List Of Figure

List of Figures

Number of Products under Development for Ependymoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Ependymoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ependymoma-Pipeline by Advantagene Inc, H2 2018

Ependymoma-Pipeline by AstraZeneca Plc, H2 2018

Ependymoma-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Ependymoma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Ependymoma-Pipeline by Celgene Corp, H2 2018

Ependymoma-Pipeline by Eli Lilly and Co, H2 2018

Ependymoma-Pipeline by Kite Pharma Inc, H2 2018

Ependymoma-Pipeline by NewLink Genetics Corp, H2 2018

Ependymoma-Pipeline by Novartis AG, H2 2018

Ependymoma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Ependymoma-Pipeline by Pfizer Inc, H2 2018

Ependymoma-Dormant Projects, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Ependymoma Therapeutic Products under Development, Key Players in Ependymoma Therapeutics, Ependymoma Pipeline Overview, Ependymoma Pipeline, Ependymoma Pipeline Assessment


Companies

Advantagene Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Eli Lilly and Co

Kite Pharma Inc

NewLink Genetics Corp

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc